New Tuberculostatic Agents Targeting Nucleic Acid Biosynthesis: Drug Design using QSAR Approaches

Nov 20, 2013Current pharmaceutical design

New tuberculosis drugs targeting genetic material production designed using QSAR methods

AI simplified

Abstract

Tuberculosis (TB) is the leading cause of death from curable infectious diseases worldwide.

  • Multidrug resistant (MDR) and extensively drug resistant (XDR) TB are significant global health concerns.
  • There is an urgent need for new anti-TB drugs to combat these resistant strains.
  • Enzymes critical for the growth of Mycobacterium tuberculosis, such as those involved in DNA and ATP production, are potential drug targets.
  • Current progress in drug discovery focuses on inhibitors of enzymes like ribonucleotide reductase, DNA gyrase, ATP synthase, and thymidylate kinase.
  • The review discusses challenges and opportunities in developing innovative tuberculostatic agents.

AI simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free